Detalles de la búsqueda
1.
Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis.
N Engl J Med
; 387(8): 704-714, 2022 08 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-36001711
2.
Serum alpha-fetoprotein and clinical outcomes in patients with advanced hepatocellular carcinoma treated with ramucirumab.
Br J Cancer
; 124(8): 1388-1397, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33531690
3.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 20(2): 282-296, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30665869
4.
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: an analysis of the phase 3 REACH study.
Br J Cancer
; 119(1): 19-26, 2018 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-29808014
5.
Exposure-response relationship of ramucirumab in East Asian patients from RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.
Gastric Cancer
; 21(2): 276-284, 2018 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-28634748
6.
Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW.
J Gastroenterol Hepatol
; 33(4): 814-824, 2018 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-28960444
7.
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Lancet
; 383(9911): 31-39, 2014 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-24094768
8.
Integrated safety analysis of umbralisib, a dual PI3Kδ/CK1ε inhibitor, in relapsed/refractory lymphoid malignancies.
Blood Adv
; 5(23): 5332-5343, 2021 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34547767
9.
Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies.
Liver Cancer
; 9(4): 440-454, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32999870
10.
Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials.
ESMO Open
; 5(4)2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32817068
11.
Association of quality of life with disease characteristics and treatment outcomes in patients with advanced gastric cancer: Exploratory analysis of RAINBOW and REGARD phase III trials.
Eur J Cancer
; 107: 115-123, 2019 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30557792
12.
Subgroup analysis of East Asian patients in REGARD: A phase III trial of ramucirumab and best supportive care for advanced gastric cancer.
Asia Pac J Clin Oncol
; 14(3): 204-209, 2018 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-29318751
13.
Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record data set.
ESMO Open
; 3(3): e000347, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29713498
14.
Baseline carcinoembryonic antigen as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma phase III trial.
Eur J Cancer
; 78: 61-69, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28412590
15.
Exposure-Response Analyses of Ramucirumab from Two Randomized, Phase III Trials of Second-line Treatment for Advanced Gastric or Gastroesophageal Junction Cancer.
Mol Cancer Ther
; 16(10): 2215-2222, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28716815
16.
Prognostic Factor Analysis of Overall Survival in Gastric Cancer from Two Phase III Studies of Second-line Ramucirumab (REGARD and RAINBOW) Using Pooled Patient Data.
J Gastric Cancer
; 17(2): 132-144, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28680718
17.
In utero DNA damage from environmental pollution is associated with somatic gene mutation in newborns.
Cancer Epidemiol Biomarkers Prev
; 11(10 Pt 1): 1134-7, 2002 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-12376523
18.
Response to Letter to the Editor, 'Pharmacokinetics partly explains the relationship between CEA level and survival of colorectal cancer patients treated with ramucirumab,' by Ibrahim et al.
Eur J Cancer
; 92: 121-122, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29433790
19.
DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population.
Carcinogenesis
; 23(8): 1321-5, 2002 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-12151350
20.
Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer.
Breast Cancer Res Treat
; 75(2): 159-66, 2002 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-12243508
Resultados
1 -
20
de 20
1
Próxima >
>>